4BIO portfolio company Orchard Therapeutics Announces $150 Million Series C Financing

Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financing. Read more at Globe Newswire.